




# PHARMACEUTICAL 2020

Sage Therapeutics Inc.  
Rank 109 of 358





# PHARMACEUTICAL 2020

Sage Therapeutics Inc.  
Rank 109 of 358



The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Sage Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 155%, being 118% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,035,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	112,128
Liabilities, Non-Current	27,367
Other Assets	39,931
Other Compr. Net Income	1,810
Other Expenses	400
Other Liabilities	0
Other Net Income	27,886
Other Revenues	6,868
Property and Equipment	9,126
Research and Development	368,815
Selling, General and Administrative Expense	345,777

Output Variable	Value in 1000 USD
Assets	1,084,150
Liabilities	139,495
Expenses	714,992
Revenues	6,868
Stockholders Equity	944,655
Net Income	-680,238
Comprehensive Net Income	-679,333
Economic Capital Ratio	155%